Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may reveal the right therapy for anxiety and depression

NCT ID NCT04426461

Knowledge-focused Sponsor: Laureate Institute for Brain Research, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study tests whether brain scans and decision-making tasks can predict how well people with anxiety and depression respond to different types of talk therapy. Participants will be randomly assigned to one of three therapies: behavioral activation, exposure-based therapy, or supportive therapy. Before and after treatment, they will undergo brain imaging and behavioral tests. The goal is to see if these measures can help personalize therapy choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Behavioral interventions: behavioral activation, exposure-based therapy, and supportive therapy
What this could lead to
If successful, this could help doctors choose the most effective therapy for each person with anxiety and depression, leading to more personalized mental health care.
What could go wrong
This is an early-stage study, and the results may not apply to everyone. The therapies are behavioral, so their success depends on individual engagement and adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

260 people

The number who actually took part.

Started

Sep 2020

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * score \>55 on both the PROMIS Anxiety and PROMIS Depression scales * score \>5 on any one item of the SDS * able to provide informed consent * report of anxiety and depressive symptoms as areas of clinical concern * sufficient English proficiency to complete procedures. Exclusion Criteria: * significant or unstable physical or mental health conditions (e.g., immediate suicidal intent) requiring medical attention * history of bipolar, psychotic, cognitive, obsessive compulsive disorder, posttraumatic stress disorder (PTSD) * history of moderate to severe substance use disorder over the past year * diagnosis of neurologic disorders * MRI contra-indications (e.g., metal in body) * uncorrected vision/hearing problems * current, regular benzodiazepine use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Depression

Contacts and locations

Locations

  • Laureate Institute for Brain Research

    Tulsa, Oklahoma, 74136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.